We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$118M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
NVIDIA
NVDA
$5.01T
| $38.1K | 0.03% |
+770
| New | +$35.7K |
|
202
Zscaler
ZS
$23B
| $37.7K | 0.03% |
+170
| New | +$31.5K |
|
203
Datadog
DDOG
$87.9B
| $37.4K | 0.03% |
+308
| New | +$31.7K |
|
204
DoorDash
DASH
$75.3B
| $36.7K | 0.02% |
+371
| New | +$32.9K |
|
205
Fortinet
FTNT
$112B
| $34.1K | 0.02% |
583
-58
| -9% | -$3.21K |
|
206
Sarepta Therapeutics
SRPT
$1.66B
| $29.4K | 0.02% |
305
-31
| -9% | -$2.97K |
|
|
CFLT
207
DELISTED
Confluent
CFLT
| $26.6K | 0.02% |
1,135
-114
| -9% | -$2.75K |
|
|
SWAV
208
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $25.9K | 0.02% |
136
-13
| -9% | -$2.46K |
|
|
VTYX
209
DELISTED
Ventyx Biosciences
VTYX
| $24.7K | 0.02% |
10,000
-2,000
| -17% | -$19K |
|
210
iShares MSCI Chile ETF
ECH
$1.01B
| $18.7K | 0.01% |
+662
| New | +$17.2K |
|
211
Phinia Inc
PHIN
$2.9B
| $12.1K | 0.01% |
399
-49
| -11% | -$1.31K |
|
212
ADC Therapeutics
ADCT
$146M
| – | – |
-1,068,468
| Closed | -$958K |
|
213
Archer Daniels Midland
ADM
$41.4B
| – | – |
-1,290
| Closed | -$97.3K |
|
214
Aflac
AFL
$63.9B
| – | – |
-3,520
| Closed | -$270K |
|
215
American International
AIG
$41.9B
| – | – |
-1,902
| Closed | -$115K |
|
|
AKRO
216
DELISTED
Akero Therapeutics
AKRO
| – | – |
-8,000
| Closed | -$405K |
|
217
Albemarle
ALB
$13.5B
| – | – |
-165
| Closed | -$28.1K |
|
218
Alkermes
ALKS
$8.82B
| – | – |
-42,500
| Closed | -$1.19M |
|
219
Allient
ALNT
$1.47B
| – | – |
-30,000
| Closed | -$928K |
|
220
Amgen
AMGN
$203B
| – | – |
-890
| Closed | -$239K |
|
221
Arista Networks
ANET
$219B
| – | – |
-1,104
| Closed | -$50.8K |
|
222
APA Corp
APA
$12.8B
| – | – |
-4,632
| Closed | -$190K |
|
223
Antero Resources
AR
$10.9B
| – | – |
-2,737
| Closed | -$69.5K |
|
224
Accuray
ARAY
$28.4M
| – | – |
-350,000
| Closed | -$952K |
|
225
Arcutis Biotherapeutics
ARQT
$3.42B
| – | – |
-165,000
| Closed | -$876K |
|
Similar funds
AIS
IVGAI
OIM
TIP
RCG
CWM
SPW
WLC
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.